Next Article in Journal
Oncology Care in the Era of Pandemics
Previous Article in Journal
Radiotherapy Side Effects: Integrating a Survivorship Clinical Lens to Better Serve Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 27
Issue 2
10.3747/co.27.6041
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Update on the Subcutaneous Administration of Rituximab in Canadian Cancer Centres

by
D. Stewart
1,*,
J.S. Aucoin
2,
T. Crosbie
3,
M. Forman
4,
E. Lye
5,
A. Christofides
6 and
A. Mitha
7
1
Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada
2
Centre Hospitalier Régional de Trois-Rivières, Université de Montréal, Trois-Rivières, QC, Canada
3
The Ottawa Hospital, Ottawa, ON, Canada
4
Burnaby Hospital, Burnaby, BC, Canada
5
Lymphoma Canada, Mississauga, ON, Canada
6
impact Medicom Inc., Toronto, ON, Canada
7
Hoffmann–La Roche, Mississauga, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(2), 113-116; https://doi.org/10.3747/co.27.6041
Submission received: 8 February 2020 / Revised: 6 March 2020 / Accepted: 5 April 2020 / Published: 1 May 2020

Abstract

Results of studies comparing subcutaneous (sc) with intravenous (iv) rituximab indicate that the two formulations are comparable in efficacy, but most patients and health care professionals prefer the sc route, commonly because of shorter chair time and reduced risk of infusion-related reactions. Recent Canadian data, including those from the scuba study reported here, support the results of earlier international studies showing a reduction in preparation and administration time with the sc formulation, lower cost of administration, and reduced drug wastage because of the fixed sc dosing. Given the significant time and cost savings of the sc formulation, that formulation is generally preferred over the iv formulation for the treatment of follicular lymphoma, diffuse large B cell lymphoma, and chronic lymphocytic leukemia.
Keywords: rituximab; subcutaneous administration rituximab; subcutaneous administration

Share and Cite

MDPI and ACS Style

Stewart, D.; Aucoin, J.S.; Crosbie, T.; Forman, M.; Lye, E.; Christofides, A.; Mitha, A. Update on the Subcutaneous Administration of Rituximab in Canadian Cancer Centres. Curr. Oncol. 2020, 27, 113-116. https://doi.org/10.3747/co.27.6041

AMA Style

Stewart D, Aucoin JS, Crosbie T, Forman M, Lye E, Christofides A, Mitha A. Update on the Subcutaneous Administration of Rituximab in Canadian Cancer Centres. Current Oncology. 2020; 27(2):113-116. https://doi.org/10.3747/co.27.6041

Chicago/Turabian Style

Stewart, D., J.S. Aucoin, T. Crosbie, M. Forman, E. Lye, A. Christofides, and A. Mitha. 2020. "Update on the Subcutaneous Administration of Rituximab in Canadian Cancer Centres" Current Oncology 27, no. 2: 113-116. https://doi.org/10.3747/co.27.6041

APA Style

Stewart, D., Aucoin, J. S., Crosbie, T., Forman, M., Lye, E., Christofides, A., & Mitha, A. (2020). Update on the Subcutaneous Administration of Rituximab in Canadian Cancer Centres. Current Oncology, 27(2), 113-116. https://doi.org/10.3747/co.27.6041

Article Metrics

Back to TopTop